Calcimimetics in the chronic kidney disease-mineral and bone disorder

被引:9
作者
Bover, Jordi [1 ]
Aguilar, Armando [1 ]
Baas, Juan P. [1 ]
Reyes, Joselyne [1 ]
Lloret, Maria-J. [1 ]
Farre, Neus [1 ]
Olaya, Mayte [1 ]
Canal, Cristina [1 ]
Marco, Helena [1 ]
Andres, Enric [1 ]
Trinidad, Pedro [1 ]
Ballarin, Jose [1 ]
机构
[1] Univ Autonoma Barcelona, Fundacio Puigvert, Dept Nephrol, Catalonia REDinREN,Inst Invest Carlos III, Barcelona 08025, Spain
关键词
Calcimimetics; Cinacalcet; Secondary hyperparathyroidism; CKD-MBD; Vascular calcification; CALCIUM-SENSING RECEPTOR; STAGE RENAL-DISEASE; CHRONIC-HEMODIALYSIS PATIENTS; HORMONE GENE-EXPRESSION; VITAMIN-D-RECEPTOR; SEVERE SECONDARY HYPERPARATHYROIDISM; TRANSFECTED HEK293 CELLS; PARATHYROID-HORMONE; DIALYSIS PATIENTS; CINACALCET HCL;
D O I
10.1177/039139880903200208
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Mineral and bone disorders (MBD) are both an early and very common complication of chronic kidney disease (CKD). It is now accepted that they represent a significant risk factor, explaining the high cardiovascular morbidity and mortality in CKD patients. During the last decade, we have been witnessing many advances in the nomenclature, classification, pathophysiology, diagnosis, and treatment of CKD and some of its complications, such as CKD-MBD. The identification of the calcium-sensing receptor (CaSR) involvement in the pathogenesis of primary and secondary hyperparathyroidism (SHPT) and the availability of a new class of drugs called calcimimetics are two outstanding examples. Cinacalcet, the only available calcimimetic, has been shown to be a very effective therapeutic tool in CKD-MBD. Many clinical trials with cinacalcet in hemodialysis patients with SHPT have shown a reduction in parathyroid hormone, calcium (Ca), phosphate (P) and Ca x P product levels, allowing far greater success in reaching therapeutic goals as recommended by international guidelines. Additionally, some studies have shown that the use of cinacalcet may improve other aspects of CKD-MBD, reducing the risk of vascular calcification and parathyroidectomy, among others. Prospective studies on dialysis patients, with hard endpoint data, are currently underway. This review summarizes the most significant aspects of calcimimimetics based on both experimental and clinical results, underlining their possibilities not only for the treatment of isolated SHPT but also for other CKD-MBD related conditions. (Int J Artif Organs 2009; 32: 108-21)
引用
收藏
页码:108 / 121
页数:14
相关论文
共 110 条
  • [1] Adynamic bone in patients with chronic kidney disease
    Andress, D. L.
    [J]. KIDNEY INTERNATIONAL, 2008, 73 (12) : 1345 - 1354
  • [2] Nonclassical aspects of differential vitamin D receptor activation
    Andress, Dennis
    [J]. DRUGS, 2007, 67 (14) : 1999 - 2012
  • [3] Calciphylaxis in patients on hemodialysis: A prevalence study
    Angelis, M
    Wong, LL
    Myers, SA
    Wong, LM
    [J]. SURGERY, 1997, 122 (06) : 1083 - 1089
  • [4] Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults
    Araya, Carlos E.
    Fennell, Robert S.
    Neiberger, Richard E.
    Dharnidharka, Vikas R.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (06): : 1161 - 1166
  • [5] Arenas MD, 2008, NEFROLOGIA, V28, P511
  • [6] Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells
    Bai, M
    Trivedi, S
    Brown, EM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (36) : 23605 - 23610
  • [7] The protein phosphatase calcineurin determines basal parathyroid hormone gene expression
    Bell, O
    Gaberman, E
    Kilav, R
    Levi, R
    Cox, KB
    Molkentin, JD
    Silver, J
    Naveh-Many, T
    [J]. MOLECULAR ENDOCRINOLOGY, 2005, 19 (02) : 516 - 526
  • [8] Effect of Cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism
    Bergua, Carlos
    Torregrosa, Jose-Vicente
    Fuster, David
    Gutierrez-Dalmau, Alex
    Oppenheimer, Federico
    Campistol, Jose M.
    [J]. TRANSPLANTATION, 2008, 86 (03) : 413 - 417
  • [9] Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients
    Block, G. A.
    Raggi, P.
    Bellasi, A.
    Kooienga, L.
    Spiegel, D. M.
    [J]. KIDNEY INTERNATIONAL, 2007, 71 (05) : 438 - 441
  • [10] Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis
    Block, GA
    Martin, KJ
    de Francisco, ALM
    Turner, SA
    Avram, MM
    Suranyi, MG
    Hercz, G
    Cunningham, J
    Abu-Alfa, AK
    Messa, P
    Coyne, DW
    Locatelli, F
    Cohen, RM
    Evenepoel, P
    Moe, SM
    Fournier, A
    Braun, J
    McCary, LC
    Zani, VJ
    Olson, KA
    Drüeke, TB
    Goodman, WG
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) : 1516 - 1525